Effects of estrogen depletion on angiogenesis in estrogen-receptor-positive breast carcinoma an immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiological response of the patients in neoadjuvant aromatase inhibitor therapy

Expert Opinion on Therapeutic Targets

Volumn 16, Issue SUPPL. 1, 2012, Pages

  Chan, Monica Sm ^a,b   Wang, Lin ^a,c   Chanplakorn, Niramol ^a,d   Tamaki, Kentaro ^e   Ueno, Takayuki ^f   Toi, Masakazu ^f   Loo, Wings Ty ^b   Chow, Louis Wc ^b   Suzuki, Takashi ^a   Sasano, Hironobu ^a  

^a TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIMED Medical Institute   (Hong Kong)

^c HARBIN MEDICAL UNIVERSITY   (China)

^d MAHIDOL UNIVERSITY   (Thailand)

^e TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KYOTO UNIVERSITY   (Japan)

Author keywords

Angiogenesis; Aromatase inhibitors; Breast cancer; Immunohistochemistry; Vasohibin

Indexed keywords

AROMATASE INHIBITOR; CD31 ANTIGEN; CELECOXIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN; ESTROGEN RECEPTOR; EXEMESTANE; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; REGULATOR PROTEIN; UNCLASSIFIED DRUG; VASOHIBIN 1;

ANGIOGENESIS; ARTICLE; ASIAN; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CELL DEATH; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; MAJOR CLINICAL STUDY; POSTMENOPAUSE; STROMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTIGENS, CD31; AROMATASE INHIBITORS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; NEOADJUVANT THERAPY; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ESTROGEN; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863255475     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2011.628938     Document Type: Article

References (52)

1. Mbeunkui F, Johann DJ Jr. Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 2009;63:571-82
2. Liotta LA, Kohn EC. The microenvironment of the tumour-host interface. Nature 2001;411:375-9
3. Jung YD, Ahmad SA, Liu W, et al. The role of the microenvironment and intercellular cross-talk in tumor angiogenesis. Semin Cancer Biol 2002;12:105-12 (Pubitemid 34680739)
4. Giordano FJ, Johnson RS. Angiogenesis: the role of the microenvironment in flipping the switch. Curr Opin Genet Dev 2001;11:35-40 (Pubitemid 32119275)
5. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64 (Pubitemid 26272076)
6. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29(6 Suppl 16):15-18
7. Furuya M, Nishiyama M, Kasuya Y, et al. Pathophysiology of tumor neovascularization. Vasc Health Risk Manag 2005;1:277-90
8. Fox SB, Generali DG, Harris AL. Breast tumour angiogenesis. Breast Cancer Res 2007;9:216-published online 18 December 2007; doi:10.1186/bcr1796
9. Makrilia N, Lappa T, Xyla V, et al. The role of angiogenesis in solid tumours: an overview. Eur J Intern Med 2009;20:663-71
10. Gupta MK, Qin RY. Mechanism and its regulation of tumor-induced angiogenesis. World J Gastroenterol 2003;9:1144-55 (Pubitemid 36805642)
11. Lorusso G, Rüegg C. The tumor microenvironment and its contribution to tumor evolution toward metastasis. Histochem Cell Biol 2008;130:1091-103
12. Folkman J. Tumor angiogenesis. In: Holland JF, Frei III E, et al. editors. Cancer medicine. 5th edition. B.C. Decker, Inc.; Canada: 2000. p. 132-52
13. Marson LP, Miller WR, Dixon JM. Angiogenesis and breast cancer. The Breast 1998;7:299-307 (Pubitemid 29060395)
14. Sato Y. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy. Int J Clin Oncol 2003;8:200-6 (Pubitemid 37122254)
15. Dvorak HF. Angiogenesis: update 2005. J Thromb Haemost 2005;3:1835-42 (Pubitemid 41716570)
16. Pietras K, Ostman A. Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 2010;316:1324-31
17. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6 (Pubitemid 20020880)
18. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992;84:1875-87 (Pubitemid 23004615)
19. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med 1991;324:1-8
20. Bottini A, Berruti A, Bersiga A, et al. Changes in microvessel density as assessed by CD34 antibodies after primary chemotherapy in human breast cancer. Clin Cancer Res 2002;8:1816-21 (Pubitemid 34633740)
21. Watanabe K, Hasegawa Y, Yamashita H, et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest 2004;114:898-907 (Pubitemid 39578717)
22. Hosaka T, Kimura H, Heishi T, et al. Vasohibin-1 expression in endothelium of tumor blood vessels regulates angiogenesis. Am J Pathol 2009;175:430-9
23. Sato Y, Sonoda H. The vasohibin family: a negative regulatory system of angiogenesis genetically programmed in endothelial cells. Arterioscler Thromb Vasc Biol 2007;27:37-41 (Pubitemid 46360378)
24. Hasan J, Byers R, Jayson GC. Intra-tumoural microvessel density in human solid tumours. Br J Cancer 2002;86:1566-77 (Pubitemid 34628110)
25. Tamaki K, Moriya T, Sato Y, et al. Vasohibin-1 in human breast carcinoma: a potential negative feedback regulator of angiogenesis. Cancer Sci 2009;100:88-94
26. Sato N, Masuda N, Saji S, et al. Neoadjuvant exemestane for 24 weeks in post-menopausal women with hormone receptor positive stage II or IIIa breast cancer (JFMC34-0601) [abstract 591]. J Clin Oncol 2009;27:15S
27. Chow LW, Yip AY, Loo WT, et al. Celecoxib anti-aromatase neoadjuvant (CAAN) trial for locally advanced breast cancer. J Steroid Biochem Mol Biol 2008;111:13-17
28. Chanplakorn N, Chanplakorn P, Suzuki T, et al. Increased estrogen sulfatase (STS) and 17beta-hydroxysteroid dehydrogenase type 1(17beta-HSD1) following neoadjuvant aromatase inhibitor therapy in breast cancer patients. Breast Cancer Res Treat 2010;120:639-48
29. Miller WR, White S, Dixon JM, et al. Proliferation, steroid receptors and clinical/pathobiologic response in breast cancer treated with letrozole. Br J Cancer 2006;94:1051-6
30. Yiu CC, Chanplakorn N, Chan MS, et al. Down-regulation of heat-shock protein 70 (HSP-70) correlated with responsiveness to neoadjuvant aromatase inhibitor therapy in breast cancer patients. Anticancer Res 2010;30:3465-72
31. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81 (Pubitemid 29220854)
32. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118-45 (Pubitemid 350003059)
33. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951s-8s (Pubitemid 40111111)
34. Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol 2008;26:814-19 (Pubitemid 351265335)
35. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6
36. Gagliardi A, Collins DC. Inhibition of angiogenesis by antiestrogens. Cancer Res 1993;53:533-5 (Pubitemid 23059432)
37. McNamara DA, Harmey J, Wang JH, et al. Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo. Eur J Surg Oncol 2001;27:714-18 (Pubitemid 33085539)
38. Soares R, Guo S, Russo J, Schmitt F. Role of the estrogen antagonist ICI 182,780 in vessel assembly and apoptosis of endothelial cells. Ultrastruct Pathol 2003;27:33-9 (Pubitemid 36293153)
39. Hyder SM, Stancel GM. Inhibition of progesterone-induced VEGF production in human breast cancer cells by the pure antiestrogen ICI 182,780. Cancer Lett 2002;181:47-53 (Pubitemid 34310661)
40. Yamaguchi Y, Hayashi S. Estrogen-related cancer microenvironment of breast carcinoma. Endocr J 2009;56:1-7
41. Miller WR, Anderson TJ, White S, et al. Aromatase inhibitors: cellular and molecular effects. J Steroid Biochem Mol Biol 2005;95:83-9 (Pubitemid 41137297)
42. Sasano H, Sato S, Ito K, et al. Effects of aromatase inhibitors on the pathobiology of the human breast, endometrial and ovarian carcinoma. Endocr Relat Cancer 1999;6:197-204 (Pubitemid 29260052)
43. Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003;63:8037-50 (Pubitemid 37466743)
44. Akli S, Bui T, Wingate H, et al. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res 2010;16:1179-90
45. Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 2001;79:103-7 (Pubitemid 34158784)
46. Miller WR. Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol 2010;118:273-6
47. Gregory CD, Pound JD. Cell death in the neighbourhood: direct microenvironmental effects of apoptosis in normal and neoplastic tissues. J Pathol 2010;223:177-94
48. Krysko DV, D'Herde K, Vandenabeele P. Clearance of apoptotic and necrotic cells and its immunological consequences. Apoptosis 2006;11:1709-26 (Pubitemid 44371047)
49. Golpon HA, Fadok VA, Taraseviciene-Stewart L, et al. Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J 2004;18:1716-18 (Pubitemid 39561661)
50. Ravichandran KS. Recruitment signals from apoptotic cells: invitation to a quiet meal. Cell 2003;113:817-20 (Pubitemid 36792025)
51. Fadok VA, Henson PM. Apoptosis: getting rid of the bodies. Curr Biol 1998;8:R693-5 (Pubitemid 28451026)
52. Chan MSM, Wang L, Chanplakorn N, et al. Effects of estrogen depletion on angiogenesis in estrogen receptor positive breast carcinoma - An immunohistochemical study of vasohibin-1 and CD31 with correlation to pathobiologic response of the patients in neoadjuvant aromatase inhibitor therapy [abstract E2104]. Proceedings of 70th Annual Meeting of the Japanese Cancer Association: Forward Strides for Cancer Research - Grounds for a Confident Future; 2011. p. 278